Intellia Therapeutics Quarterly Income Statement
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Intellia Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Intellia Therapeutics generated $7.7 million in revenue, down 46.2% from the same quarter a year earlier. Intellia Therapeutics reported a net loss of $106.6 million, compared with a loss of $101.3 million a year earlier. Operating margin was -1472.3%.
Diluted earnings per share came in at -$0.80.
Summary generated from market data by MetaCap's automated system. Methodology
Intellia Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.66M | 15.05M | 23.02M | 13.78M | 14.24M | 16.63M | 12.87M | 9.11M | 6.96M | 28.93M | -1.92M | 11.99M |
| Revenue growth (YoY) | -46.23% | -9.50% | +78.79% | +51.27% | +104.76% | -42.54% | — | -24.02% | -48.82% | +129.53% | -114.12% | -9.60% |
| Research & Development | 82.59M | 80.74M | 88.65M | 94.75M | 97.03M | 108.43M | 116.88M | 123.38M | 114.21M | 111.85M | 108.98M | 113.70M |
| Operating Income | -112.76M | -100.53M | -98.71M | -111.48M | -110.00M | -120.81M | -136.45M | -144.77M | -139.04M | -114.00M | -139.89M | -131.11M |
| Other Income (Expense) | 6.13M | 4.30M | 2.92M | 10.15M | 8.74M | 6.48M | 7.55M | 9.06M | -7.93M | 6.57M | 7.73M | 8.88M |
| Net Income | -106.63M | -96.23M | -95.79M | -101.32M | -101.25M | -114.33M | -128.90M | -135.71M | -146.97M | -107.44M | -132.16M | -122.22M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.80 | -0.81 | -0.81 | -0.92 | -0.98 | -1.10 | -1.27 | -1.34 | -1.52 | -1.12 | -1.47 | -1.38 |
| EPS (Diluted) | -0.80 | -0.81 | -0.81 | -0.92 | -0.98 | -1.10 | -1.27 | -1.34 | -1.52 | -1.12 | -1.47 | -1.38 |
| Shares Outstanding (Basic) | 133.48M | 118.49M | — | 110.19M | 103.73M | 103.50M | — | 101.00M | 96.97M | 95.50M | — | 88.64M |
| Shares Outstanding (Diluted) | 133.48M | 118.49M | — | 110.19M | 103.73M | 103.50M | — | 101.00M | 96.97M | 95.50M | — | 88.64M |
| EBITDA | -110.66M | -98.33M | -96.33M | -109.08M | -107.50M | -118.31M | -133.88M | -142.17M | -136.44M | -111.49M | -137.43M | -128.82M |
| Operating Margin | -1472.25% | -668.08% | -428.86% | -808.86% | -772.17% | -726.57% | -1059.86% | -1588.96% | -1998.61% | -394.00% | 7297.44% | -1093.29% |
| Net Margin | -1392.27% | -639.49% | -416.15% | -735.19% | -710.81% | -687.61% | -1001.23% | -1489.54% | -2112.62% | -371.30% | 6894.16% | -1019.21% |
This table shows 12 quarterly periods of Intellia Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow NTLA's reporting calendar. What is a income statement?